Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 9S-[(1-oxohexadecyl)oxy]-octadecanoic acid
- Correlated keywords
- FAHFA mediator S enantiomer 9-PAHSA branched fatty acid ester fatty acid
- Product Overview:
9-PAHSA (Item No. 17037) is a newly identified endogenous lipid that belongs to a collection of branched fatty acid esters of hydroxy fatty acids (FAHFAs). It is found in wild-type and AG4OX mice, as well as humans, and is reduced in the serum and adipose tissues of insulin-resistant humans.{27644} 9-PAHSA improves glucose tolerance, stimulates insulin secretion, and has anti-inflammatory effects in mice.{27644} 9(S)-PAHSA is the S enantiomer of 9-PAHSA. There are no published reports on the activity of this enantiomer. The use of this optically-active FAHFA product (the “Product”) is covered by U.S. Patent No. 10,240,025 and corresponding foreign counterpart applications. These patents and applications are licensed by Cayman pursuant to an agreement with BT Food, Drug and Personal Care, LLC, and this Product is sold exclusively for research and development purposes only. Product may not be used for human studies, veterinary use or diagnostics, clinical trial work, clinical diagnostics, or any other clinical trial or approval activities related to humans or animals. This limited label license does not grant any right to use the Product or a Product derivative in commercial products or services. This Product may not be re-sold, distributed, or repackaged unless by official Cayman distributors. For information on commercial rights, please contact the outlicensing department at jforest@biosynthetic.com.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.